Global R&D Pipeline
My Favorite
Hot Targets:
DLL3
Back
Total number of drugs
85
Phase II and later clinical stages
8.2%
Involving companies
114
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alveltamig | Alveltamig | Trispecific T-cell engager (TriTE) | Neoplasms Urogenital Diseases Respiratory Diseases | CD3 stimulants DLL3 inhibitors | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | Suzhou Zelgen Biopharmaceuticals Co., Ltd. | Phase 3 | Phase 3 | - | - | - | Breakthrough Therapy（China） Orphan Drug（United States） | - | - | - | - | Alveltamig | - | - | detail > | |
| TARLATAMAB-DLLE | TARLATAMAB-DLLE | Bispecific T-cell Engager (BiTE) | Neoplasms Respiratory Diseases Nervous System Diseases Digestive System Disorders Endocrinology and Metabolic Disease Other Diseases Infectious Diseases Otorhinolaryngologic Diseases Skin and Musculoskeletal Diseases Urogenital Diseases | CD3 stimulants DLL3 inhibitors | Amgen, Inc. | Amgen, Inc. BeiGene (Beijing) Co. Ltd. Amgen Ltd. Amgen Australia Pty Ltd. BeOne Medicines Ltd. | Approved | NDA/BLA | United States Japan United Kingdom Canada Australia South Korea | 2024-05-16 | - | Accelerated Approval（United States） Orphan Drug（Australia） Orphan Drug（European Union） Orphan Drug（South Korea） Priority Review（China） Priority Review（United States） Orphan Drug（Japan） | - | - | - | - | TARLATAMAB-DLLE | - | - | detail > | |
| Peluntamig | Peluntamig | Bispecific antibody | Neoplasms Respiratory Diseases Urogenital Diseases Digestive System Disorders Endocrinology and Metabolic Disease Other Diseases | CD47 inhibitors DLL3 inhibitors | Phanes Therapeutics, Inc. | Baoxiang Technology (Shenzhen) Co., Ltd. Phanes Therapeutics, Inc. | Phase 2 | Phase 2 | - | - | - | Fast Track（United States） Orphan Drug（United States） | - | - | - | - | Peluntamig | - | - | detail > | |
| DLL3-CAR-NK Cells(Tianjin Medical University Cancer Institute and Hospital) | DLL3-CAR-NK Cells(Tianjin Medical University Cancer Institute and Hospital) | CAR-NK | Neoplasms Respiratory Diseases | DLL3 modulators Immunologic cytotoxicity Natural killer cell replacements | Tianjin Medical University Cancer Institute and Hospital | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | DLL3-CAR-NK Cells(Tianjin Medical University Cancer Institute and Hospital) | - | - | detail > | |
| Zocilurtatug Pelitecan | Zocilurtatug Pelitecan | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases Digestive System Disorders Endocrinology and Metabolic Disease Other Diseases | DLL3 inhibitors TOP1 inhibitors | Suzhou Medilink Therapeutics Ltd. | Zai Lab (Shanghai) Co., Ltd. Zai Lab Ltd. (United States) Suzhou Medilink Therapeutics Ltd. | Phase 3 | Phase 1/2 | - | - | - | Fast Track（United States） Orphan Drug（United States） | - | Cleavable linker | YL0010014 | 8 | Zocilurtatug Pelitecan | IgG1 - nd | - | detail > | |
| Obrixtamig | Obrixtamig | Bispecific T-cell Engager (BiTE) | Neoplasms Infectious Diseases Endocrinology and Metabolic Disease Respiratory Diseases Other Diseases Nervous System Diseases | CD3 stimulants DLL3 inhibitors | Boehringer Ingelheim GmbH | Boehringer Ingelheim GmbH Boehringer Ingelheim Pharma GmbH & Co., KG Boehringer Ingelheim International GmbH | Phase 2 | Phase 2 | - | - | - | Fast Track（United States） Orphan Drug（European Union） Orphan Drug（United States） | - | - | - | - | Obrixtamig | - | - | detail > | |
| HRA00130-C004 | HRA00130-C004 | Antibody drug conjugate (ADC) | Neoplasms Respiratory Diseases | DLL3 inhibitors TOP1 inhibitors | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | Cleavable linker | DXh | - | HRA00130-C004 | - | - | detail > | |
| DLL3 targeted CAR-T(Shanghai Pharma) | DLL3 targeted CAR-T(Shanghai Pharma) | CAR-T | Neoplasms Respiratory Diseases | DLL3 modulators | Shanghai Pharmaceuticals Holding Co., Ltd. | Shanghai Pharmaceuticals Holding Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | DLL3 targeted CAR-T(Shanghai Pharma) | - | - | detail > | |
| DB-1314 | DB-1314 | Antibody drug conjugate (ADC) | Neoplasms | DLL3 inhibitors | Duality Biologics (Suzhou) Co., Ltd. | Duality Biologics (Suzhou) Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | DB-1314 | - | - | detail > | |
| rovalpituzumab | rovalpituzumab | Monoclonal antibody | Neoplasms | DLL3 inhibitors | Stemcentrx, Inc. | Stemcentrx, Inc. | Clinical | - | - | - | - | - | - | - | - | - | rovalpituzumab | - | - | detail > |
Total 85 data
1
2
3
4
5
6
7
8
9
